|

Part C: OSE-279 600 mg - HLA-A2 negative Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • OSE Immunotherapeutics1

Indications

  • Solid Advanced Tumor1
  • NSCLC (Non-small Cell Lung Cancer)1
  • Lymphoma1
  • Lung Cancer1
  • Cancer1

Other1 trial

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.